Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Scholar Rock Holding Corp (NQ: SRRK )

8.580 +0.010 (+0.12%)
Streaming Delayed Price Updated: 12:05 PM EDT, Sep 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 198,477
Open 8.580
Bid (Size) 8.550 (3)
Ask (Size) 8.580 (1)
Prev. Close 8.570
Today's Range 8.460 - 8.820
52wk Range 5.940 - 21.17
Shares Outstanding 80,032,623
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity
From Scholar Rock
Via Business Wire

Performance

YTD
-50.97%
-50.97%
1 Month
-7.94%
-7.94%
3 Month
-2.28%
-2.28%
6 Month
-35.00%
-35.00%
1 Year
+37.50%
+37.50%

More News

Read More
Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer
From Scholar Rock
Via Business Wire
Scholar Rock to Participate in Upcoming Investor Conferences
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
SRRK Stock Earnings: Scholar Rock Holding Beats EPS for Q2 2024
Via InvestorPlace
Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress
From Scholar Rock
Via Business Wire
Scholar Rock to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting
From Scholar Rock
Via Business Wire
Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Scholar Rock
Via Business Wire
Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity
From Scholar Rock
Via Business Wire
Scholar Rock to Participate in Upcoming Investor Conferences
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock to Host Investor Day on May 22, 2024
From Scholar Rock
Via Business Wire
SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q1 2024
Via InvestorPlace
Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress
From Scholar Rock
Via Business Wire
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
Via InvestorPlace
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock Is A Potential M&A Target, Its Exploration of Obesity Market Garners Interest: Analyst
Via Benzinga
SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q4 2023
Via InvestorPlace
Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress
From Scholar Rock
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.